New drug cocktail shows promise for Hard-to-Treat lung cancer
NCT ID NCT04042558
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of chemotherapy (carboplatin or cisplatin plus pemetrexed) and immunotherapy (atezolizumab, with or without bevacizumab) in 150 people with advanced non-squamous non-small cell lung cancer that has EGFR, ALK, or ROS1 mutations and has progressed after targeted therapy. The main goal was to see how many patients' tumors shrank or disappeared after four cycles of treatment. The study also tracked how long patients lived without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin, Pemetrexed, Atezolizumab, and Bevacizumab (a combination of chemotherapy and immunotherapy drugs)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose targeted therapies have stopped working.
What could go wrong
This is a phase 2 trial, so it is still early. The combination may cause significant side effects, and not all patients may benefit. Results need confirmation in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHD Vendée La Roche sur Yon
La Roche-sur-Yon, France
-
CHIC
Créteil, France
-
CHR Orléans
Orléans, France
-
CHU
Angers, France
-
CHU
Grenoble, France
-
CHU
Lille, France
-
CHU
Pierre-Bénite, France
-
CHU
Rennes, France
-
CHU
Rouen, France
-
CHU
Toulouse, France
-
CHU Gabriel MONTPIED
Clermont-Ferrand, France
-
CHU Limoges
Limoges, France
-
CHU Lyon Louis Pradel
Bron, France
-
CHU Lyon, Croix-Rousse,
Lyon, France
-
CHU Réunion St Denis
La Réunion, France
-
CHU Réunion St Pierre
La Réunion, France
-
CHU-Hôpital MORVAN
Brest, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Hospitalier
Annecy, France
-
Centre Hospitalier
Villefranche, France
-
Centre Hospitalier Bretagne Atlantique
Vannes, France
-
Centre Léon Bérard
Lyon, France
-
Centre Paul Strauss
Strasbourg, France
-
HIA Percy
Percy, France
-
HIA R.Picqué
Villenave-d'Ornon, France
-
HIA St Anne
Toulon, France
-
Hopital Foch
Paris, France
-
Hôpital Haut Lévêque,Centre François Magendie
Pessac, France
-
Hôpital Nord
Marseille, France
-
ICLN, St Priez en Jarez
Saint-Priest-en-Jarez, France
-
institut Curie
Paris, France